The Economic Evaluation of HPV Vaccination as a Prevention of Non-Cervical Cancer Using Modelling Approaches: A Systematic Review

Open Access

Issue		BIO Web Conf. Volume 75, 2023 The 5^th International Conference on Bioinformatics, Biotechnology, and Biomedical Engineering (BioMIC 2023)


Article Number		05018
Number of page(s)		15
Section		Big Data for Public Health Policy
DOI		https://doi.org/10.1051/bioconf/20237505018
Published online		15 November 2023

C. De Martel, D. Georges, F. Bray, J. Ferlay, and G. M. Clifford, “Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis,” Lancet Glob. Health, vol. 8, no. 2, pp. e180–e190, Feb. 2020, doi: 10.1016/S2214-109X(19)30488-7. [CrossRef] [Google Scholar]
L. Bruni, A. Saura-Lázaro, A. Montoliu, M. Brotons, L. Alemany, M. S. Diallo, O. Z. Afsar, D. S. LaMontagne, L. Mosina, M. Contreras, M. Velandia-González, R. Pastore, M. Gacic-Dobo, and P. Bloem, “HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019,” Prev. Med., vol. 144, p. 106399, Mar. 2021, doi: 10.1016/j.ypmed.2020.106399. [CrossRef] [Google Scholar]
G. K. Shapiro, “HPV Vaccination: An Underused Strategy for the Prevention of Cancer,” Curr. Oncol., vol. 29, no. 5, pp. 3780–3792, May 2022, doi: 10.3390/curroncol29050303. [CrossRef] [Google Scholar]
K. Zou, Y. Huang, and Z. Li, “Prevention and treatment of human papillomavirus in men benefits both men and women,” Front. Cell. Infect. Microbiol., vol. 12, p. 1077651, Nov. 2022, doi: 10.3389/fcimb.2022.1077651. [CrossRef] [Google Scholar]
L. Bruni, A. Saura-Lázaro, A. Montoliu, M. Brotons, L. Alemany, M. S. Diallo, O. Z. Afsar, D. S. LaMontagne, L. Mosina, M. Contreras, M. Velandia-González, R. Pastore, M. Gacic-Dobo, and P. Bloem, “HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010– 2019,” Prev. Med., vol. 144, p. 106399, Mar. 2021, doi: 10.1016/j.ypmed.2020.106399. [CrossRef] [Google Scholar]
M. J. Page, J. E. McKenzie, P. M. Bossuyt, I. Boutron, T. C. Hoffmann, C. D. Mulrow, L. Shamseer, J. M. Tetzlaff, E. A. Akl, S. E. Brennan, R. Chou, J. Glanville, J. M. Grimshaw, A. Hrobjartsson, M. M. Lalu, T. Li, E. W. Loder, E. Mayo-Wilson, S. McDonald, L. A. McGuinness, L. A. Stewart, J. Thomas, A. C. Tricco, V. A. Welch, P. Whiting, and D. Moher, “The PRISMA 2020 statement: an updated guideline for reporting systematic reviews,” BMJ, p. n71, Mar. 2021, doi: 10.1136/bmj.n71. [CrossRef] [PubMed] [Google Scholar]
D. Husereau, M. Drummond, S. Petrou, C. Carswell, D. Moher, D. Greenberg, F. Augustovski, A. H. Briggs, J. Mauskopf, E. Loder, and on behalf of the CHEERS Task Force, “Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement,” BMJ, vol. 346, no. mar 25 1, pp. f1049–f1049, Mar. 2013, doi: 10.1136/bmj.f1049. [CrossRef] [PubMed] [Google Scholar]
“Konversi Mata Uang Investing.com,” Investing.com Indonesia. Accessed: Sep. 05, 2023. [Online]. Available: https://id.investing.com/currency-converter/ [Google Scholar]
“Inflation Calculator | Find US Dollar’s Value From 1913-2023.” Accessed: Sep. 05, 2023. [Online]. Available: https://www.usinflationcalculator.com/ [Google Scholar]
T. H. Cheung, S. S. Y. Cheng, D. C. Hsu, Q. W.- L. Wong, A. Pavelyev, A. Walia, K. Saxena, and V. S. Prabhu, “The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong,” Cost Eff. Resour. Alloc., vol. 19, no. 1, p. 75, Dec. 2021, doi: 10.1186/s12962-021-00328-x. [CrossRef] [Google Scholar]
M. Jit, M. Brisson, J.-F. Laprise, and Y. H. Choi, “Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model,” BMJ, vol. 350, no. jan06 14, pp. g7584–g7584, Jan. 2015, doi: 10.1136/bmj.g7584. [CrossRef] [PubMed] [Google Scholar]
H. W. Chesson, E. Meites, D. U. Ekwueme, M. Saraiya, and L. E. Markowitz, “Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States,” Vaccine, vol. 36, no. 29, pp. 4362–4368, Jul. 2018, doi: 10.1016/j.vaccine.2018.04.071. [CrossRef] [PubMed] [Google Scholar]
H. W. Chesson, E. Meites, D. U. Ekwueme, M. Saraiya, and L. E. Markowitz, “Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model,” Vaccine, vol. 38, no. 50, pp. 8032–8039, Nov. 2020, doi: 10.1016/j.vaccine.2020.10.019. [CrossRef] [PubMed] [Google Scholar]
T. H. Cheung, S. S. Y. Cheng, D. Hsu, Q. WingLei Wong, A. Pavelyev, I. Sukarom, and K. Saxena, “Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong,” Hum. Vaccines Immunother., vol. 19, no. 2, p. 2184605, 2023, doi: 10.1080/21645515.2023.2184605. [Google Scholar]
S. E. Choi, A. Choudhary, J. Huang, S. Sonis, A. R. Giuliano, and A. Villa, “Increasing HPV vaccination coverage to prevent oropharyngeal cancer: A cost-effectiveness analysis,” Tumour Virus Res., vol. 13, p. 200234, Jun. 2022, doi: 10.1016/j.tvr.2021.200234. [CrossRef] [Google Scholar]
P. Cody, K. Tobe, M. Abe, and E. H. Elbasha, “Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study,” BMC Infect. Dis., vol. 21, no. 1, p. 11, Jan. 2021, doi: 10.1186/s12879-02005632-0. [CrossRef] [Google Scholar]
R. Linertová, C. Guirado-Fuentes, J. Mar-Medina, and C. Teljeur, “Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain,” Hum. Vaccines Immunother., vol. 18, no. 6, p. 2127983, Nov. 2022, doi: 10.1080/21645515.2022.2127983. [CrossRef] [PubMed] [Google Scholar]
F. S. Mennini, P. Bonanni, F. Bianic, C. de Waure, G. Baio, G. Plazzotta, M. Uhart, A. Rinaldi, and N. Largeron, “Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy,” Cost Eff. Resour. Alloc. CE, vol. 15, p. 11, 2017, doi: 10.1186/s12962-017-0073-8. [CrossRef] [Google Scholar]
S. Simoens, A. Bento-Abreu, B. Merckx, S. Joubert, S. Vermeersch, A. Pavelyev, S. Varga, and E. Morais, “Health Impact and CostEffectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium,” Front. Pharmacol., vol. 12, p. 628434, Apr. 2021, doi: 10.3389/fphar.2021.628434. [CrossRef] [Google Scholar]
M. T. Wahab, R. K. J. Tan, A. R. Cook, and K. Prem, “Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: A modelling-based costeffectiveness analysis,” Vaccine, vol. 41, no. 12, pp. 1934–1942, Mar. 2023, doi: 10.1016/j.vaccine.2023.02.025. [CrossRef] [PubMed] [Google Scholar]
J. J. M. Simons, N. Vida, T. A. Westra, and M. J. Postma, “Cost-effectiveness analysis of a genderneutral human papillomavirus vaccination program in the Netherlands,” Vaccine, vol. 38, no. 30, pp. 4687–4694, Jun. 2020, doi: 10.1016/j.vaccine.2020.05.031. [CrossRef] [PubMed] [Google Scholar]
E. Wolff, K. M. Elfström, H. Haugen Cange, S. Larsson, H. Englund, P. Sparén, and A. Roth, “Cost-effectiveness of sex-neutral HPVvaccination in Sweden, accounting for herdimmunity and sexual behaviour,” Vaccine, vol. 36, no. 34, pp. 5160–5165, Aug. 2018, doi: 10.1016/j.vaccine.2018.07.018. [CrossRef] [PubMed] [Google Scholar]
L. Zhang, D. G. Regan, J. J. Ong, M. Gambhir, E. P. F. Chow, H. Zou, M. Law, J. Hocking, and C. K. Fairley, “Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effective,” Vaccine, vol. 35, no. 37, pp. 4923–4929, Sep. 2017, doi: 10.1016/j.vaccine.2017.07.078. [CrossRef] [PubMed] [Google Scholar]
Y. Li, Y.-F. Lin, X. Wu, X. Zhou, T. Tian, Z. Guo, L. Fu, L. Yang, Z. Lu, S. Fan, Y. Lu, W. Ke, and H. Zou, “Effectiveness and cost-effectiveness of human papillomavirus vaccination strategies among men who have sex with men in China: a modeling study,” Front. Immunol., vol. 14, p. 1197191, Jun. 2023, doi: 10.3389/fimmu.2023.1197191. [CrossRef] [Google Scholar]
L. Majed, X. Bresse, N. El Mouaddin, A. Schmidt, V. J. Daniels, A. Pavelyev, L. Levy-Bachelot, and E. Elbasha, “Public health impact and costeffectiveness of a nine-valent gender-neutral HPV vaccination program in France,” Vaccine, vol. 39, no. 2, pp. 438–446, Jan. 2021, doi: 10.1016/j.vaccine.2020.10.089. [CrossRef] [PubMed] [Google Scholar]
H. W. Chesson, E. Meites, D. U. Ekwueme, M. Saraiya, and L. E. Markowitz, “Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United States,” Hum. Vaccines Immunother., vol. 15, no. 7–8, pp. 1942–1948, 2019, doi: 10.1080/21645515.2019.1603562. [CrossRef] [PubMed] [Google Scholar]
J. J. M. Simons, N. Vida, T. A. Westra, and M. J. Postma, “Cost-effectiveness analysis of a genderneutral human papillomavirus vaccination program in the Netherlands,” Vaccine, vol. 38, no. 30, pp. 4687–4694, Jun. 2020, doi: 10.1016/j.vaccine.2020.05.031. [CrossRef] [PubMed] [Google Scholar]
Indonesian HTA Commitee, Health Technology Assessment (HTA) Guideline.pdf. Ministry of Health Republic of Indonesia, 2017. [Google Scholar]
“How do you choose the best sampling method for Monte Carlo simulation in OR?” Accessed: Sep. 05, 2023. [Online]. Available: https://www.linkedin.com/advice/3/how-do-you-choose-best-sampling-method-monte [Google Scholar]
S. Abidi, S. Labani, A. Singh, S. Asthana, and P. Ajmera, “Economic evaluation of human papillomavirus vaccination in the Global South: a systematic review,” Int. J. Public Health, vol. 65, no. 7, pp. 1097–1111, Sep. 2020, doi: 10.1007/s00038-020-01431-1. [CrossRef] [PubMed] [Google Scholar]
D. Setiawan, M. P. Oktora, R. Hutubessy, A. Riewpaiboon, and M. J. Postma, “The healtheconomic studies of HPV vaccination in Southeast Asian countries: a systematic review,” Expert Rev. Vaccines, vol. 16, no. 9, pp. 933–943, Sep. 2017, doi: 10.1080/14760584.2017.1357472. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.